Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 13;161:105250. doi: 10.1016/j.phrs.2020.105250

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Author(s)

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 3 — Heatmap of potential DDI between drugs used in the course of COVID-19 and co-medications. The co-medications are putatively used for treatment of identified comorbidities (hypertension, cerebrovascular, cardiovascular, diabetes and COPD) based on results of the meta-analysis. Anti-viral drugs LPV/r and AZM interact with drugs prescribed for cardiometabolic syndrome. Potential interactions were predicting using www.covid19-druginteractions.org database. Abbreviations: atazanavir (ATV), azithromycin (AZM) darunavir/cobicistat (DRV/c), lopinavir/ritonavir (LPV/r), remdesivir/GS-5734 (RDV), favipiravir (FAVI), chloroquine (CLQ), hydroxychloroquine (HCLQ), nitazoxanide (NITA), ribavirin (RBV), tocilizumab (TCZ), interferon β-1a (IFN-β-1a) and oseltamivir (OSV).